Emicizumab: a novel drug in hemophilia A prophylaxis – a narrative review

References

• Bhardwaj R, Rath G, Goyal AK. Advancement in the treatment of haemophilia. Int J Biol Macromol. 2018;118:289–295.
   PubMed Web of Science ®Google Scholar
• Trinchero A, Sholzberg M, Matino D. The evolution of hemophilia care: clinical and laboratory advances, opportunities, and challenges. Hamostaseologie. 2020;40(3):311–321.
   PubMedGoogle Scholar
• Mancuso ME, Mahlangu JN, Pipe SW. The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing. Lancet Lond Engl. 2021;397(10274):630–640.
   PubMed Web of Science ®Google Scholar
• Stromer W, Pabinger I, Ay C, et al. Pain management in hemophilia: expert recommendations. Wien Klin Wochenschr. 2021;133(19–20):1042–1056.
   PubMed Web of Science ®Google Scholar
• Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1–47.
   PubMed Web of Science ®Google Scholar
• Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemoph Off J World Fed Hemoph. 2020;26(Suppl 6): 1–158.
   PubMedGoogle Scholar
• Måseide RJ, Berntorp E, Astermark J, et al. Haemophilia early arthropathy detection with ultrasound and haemophilia joint health score in the moderate haemophilia (MoHem) study. Haemoph Off J World Fed Hemoph. 2021;27:e253–9.
   PubMed Web of Science ®Google Scholar
• Di Minno MND, Ambrosino P, Franchini M, et al. Arthropathy in patients with moderate hemophilia a: a systematic review of the literature. Semin Thromb Hemost. 2013;39(7):723–731.
   PubMed Web of Science ®Google Scholar
• Marchesini E, Morfini M, Valentino L. Recent advances in the treatment of hemophilia: a review. Biol Targets Ther. 2021;15:221–235.
   PubMed Web of Science ®Google Scholar
• Blair HA. Emicizumab: a review in haemophilia A. Drugs. 2019;79(15):1697–1707.
   PubMed Web of Science ®Google Scholar
• Chhabra A, Spurden D, Fogarty PF, et al. Real-world outcomes associated with standard half-life and extended half-life factor replacement products for treatment of haemophilia A and B. Blood Coagul Fibrinolysis Int J Haemost Thromb. 2020;31(3):186–192.
   PubMed Web of Science ®Google Scholar
• Nathwani AC, Davidoff AM, Tuddenham EGD. Gene therapy for hemophilia. Hematol Oncol Clin North Am. 2017;31(5):853–868.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Merchán EC, De Pablo-Moreno JA, Liras A. Gene therapy in hemophilia: recent advances. Int J Mol Sci. 2021;22(14):7647.
   PubMed Web of Science ®Google Scholar
• Ohmori T. Advances in gene therapy for hemophilia: basis, current status, and future perspectives. Int J Hematol. 2020;111(1):31–41.
   PubMed Web of Science ®Google Scholar
• Miesbach W, Klamroth R. The patient experience of gene therapy for hemophilia: qualitative interviews with trial patients. Patient Prefer Adherence. 2020;14:767–770.
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia a with inhibitors. N Engl J Med. 2017;377(9): 809–818.
   PubMed Web of Science ®Google Scholar
• Schmitt C, Adamkewicz JI, Xu J, et al. Pharmacokinetics and pharmacodynamics of emicizumab in persons with hemophilia a with factor VIII inhibitors: HAVEN 1 study. Thromb Haemost. 2021;121(3):351–360.
   PubMedGoogle Scholar
• Kitazawa T, Esaki K, Tachibana T, et al. Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens. Thromb Haemost. 2017;117(7):1348–1357.
   PubMed Web of Science ®Google Scholar
• Kitazawa T, Shima M. Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity. Int J Hematol. 2020;111(1):20–30.
   PubMed Web of Science ®Google Scholar
• Uchida N, Sambe T, Yoneyama K, et al. A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. Blood. 2016;127(13):1633–1641.
   PubMed Web of Science ®Google Scholar
• Adamkewicz JI, Chen DC, Effects P-PI. Interferences of emicizumab, a humanised bispecific antibody mimicking activated factor VIII cofactor function, on coagulation assays. Thromb Haemost. 2019;119(7):1084–1093.
   PubMed Web of Science ®Google Scholar
• Parisi K, Kumar A. Emicizumab. Treasure Island (FL): StatPearls Publishing; 2022 https://www.ncbi.nlm.nih.gov/books/NBK559180/ Accessed 22 July 2022.
   Google Scholar
• Pipe SW, Shima M, Lehle M, et al. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol. 2019;6(6): e295–305.
   PubMed Web of Science ®Google Scholar
• Young G, Liesner R, Chang T, et al. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019;134(24): 2127–2138.
   PubMed Web of Science ®Google Scholar
• Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia a without inhibitors. N Engl J Med. 2018;379(9): 811–822.
   PubMed Web of Science ®Google Scholar
• Schmitt C, Emrich T, Chebon S, et al. Low immunogenicity of emicizumab in persons with haemophilia A. Haemoph Off J World Fed Hemoph. 2021;27(6):984–992.
   PubMed Web of Science ®Google Scholar
• Harroche A, Sefiane T, Desvages M, et al. Non-inhibitory antibodies inducing increased emicizumab clearance in a severe haemophilia A inhibitor patient. Haematologica. 2021.
   PubMed Web of Science ®Google Scholar
• Kaneda M, Kawasaki R, Matsumoto N, et al. Detailed analysis of anti-emicizumab antibody decreasing drug efficacy, using plasma samples from a patient with hemophilia A. J Thromb Haemost JTH. 2021;19(12):2938–2946.
   PubMed Web of Science ®Google Scholar
• Knoebl P, Thaler J, Jilma P, et al. Emicizumab for the treatment of acquired hemophilia A. Blood. 2021;137(3):410–419.
   PubMed Web of Science ®Google Scholar
• Ahn JH, Jung N, Shim YJ, et al. Emicizumab prophylaxis in a Korean child with severe hemophilia A and high titer inhibitor: a case report. BLOOD Research. 2021;56(1):44–46.
   PubMed Web of Science ®Google Scholar
• Lefèvre CR, Jaffré A, Pontis A, et al. Management of a high-risk surgery with emicizumab and factor VIII in a child with a severe hemophilia A and inhibitor. TH Open Companion J Thromb Haemost. 2021;5. e163–5.
   PubMedGoogle Scholar
• Weyand AC, Flood VH, Shavit JA, et al. Efficacy of emicizumab in a pediatric patient with type 3 von Willebrand disease and alloantibodies. Blood Adv. 2019;3(18):2748–2750.
   PubMed Web of Science ®Google Scholar
• Abarca-Villaseca V, Breakthrough Bleeding S-AV. Episodes at minimum and improvement in quality of life in a child with severe hemophilia a with inhibitors treated with emicizumab: a case report from Chile. Am J Case Rep. 2021;22:e929598.
   PubMed Web of Science ®Google Scholar
• Bush KA, Lucas TL, Haley KM, et al. Initiation of emicizumab prophylaxis in an infant with haemophilia A and subdural haemorrhage. Haemoph Off J World Fed Hemoph. 2020;26:e353–5.
   PubMedGoogle Scholar
• Shima M, Hanabusa H, Taki M, et al. Factor VIII-Mimetic function of humanized bispecific antibody in hemophilia A. N Engl J Med. 2016;374(21):2044–2053.
   PubMed Web of Science ®Google Scholar
• Klamroth R. A new era of treatment for patients with haemophilia A? Hämostaseologie. 2017;37(3):216–218.
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Mahlangu JN, Bujan W, et al. The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 study. Haemoph Off J World Fed Hemoph. 2019;25(1):33–44.
   PubMed Web of Science ®Google Scholar
• Shima M, Nagao A, Taki M, et al. Long-term safety and efficacy of emicizumab for up to 5.8 years and patients’ perceptions of symptoms and daily life: a phase 1/2 study in patients with severe haemophilia A. Haemoph Off J World Fed Hemoph. 2021;27(1):81–89.
   PubMed Web of Science ®Google Scholar
• Barg AA, Livnat T, Budnik I, et al. Emicizumab treatment and monitoring in a paediatric cohort: real-world data. Br J Haematol. 2020;191(2):282–290.
   PubMed Web of Science ®Google Scholar
• Cortesi PA, Castaman G, Trifirò G, et al. Cost-Effectiveness and budget impact of emicizumab prophylaxis in haemophilia A patients with inhibitors. Thromb Haemost. 2020;120(2):216–228.
   PubMed Web of Science ®Google Scholar
• Brown LJ, La HA, Li J, et al. The societal burden of haemophilia A. III - The potential impact of emicizumab on costs of haemophilia A in Australia. Haemoph Off J World Fed Hemoph. 2020;26(Suppl 5):21–29.
   PubMedGoogle Scholar
• Shima M, Nogami K, Nagami S, et al. A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors. Haemoph Off J World Fed Hemoph. 2019;25(6):979–987.
   PubMed Web of Science ®Google Scholar
• Polack B, Trossaërt M, Cousin M, et al. Cost‐effectiveness of emicizumab vs bypassing agents in the prevention of bleeding episodes in haemophilia A patients with anti‐FVIII inhibitors in France. Haemophilia. 2021;28(1): 27.
   PubMedGoogle Scholar
• Lee H, Cho H, Han JW, et al. Cost‐utility analysis of emicizumab prophylaxis in haemophilia A patients with factor VIII inhibitors in Korea. Haemophilia. 2021;28(1):27.
   PubMedGoogle Scholar
• Gundabolu K, Goldsweig A, Bhatt VR, et al. ST-Segment elevation myocardial infarction (STEMI) and pulmonary embolism in a hemophilia a patient receiving emicizumab and recombinant activated factor VII. Haemoph Off J World Fed Hemoph. 2020;26:e5–8.
   PubMed Web of Science ®Google Scholar
• Holzmann J, Coulsen H, Poulsen W, et al. Emicizumab therapy in a haemophilia patient with previous pulmonary embolism. J Paediatr Child Health. 2020;56(12):2001–2002.
   PubMed Web of Science ®Google Scholar
• Lewandowska M, Randall N, Bakeer N, et al. Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: real-world experience from a large comprehensive treatment centre in the US. Haemoph Off J World Fed Hemoph. 2021;27(1):90–99.
   PubMed Web of Science ®Google Scholar
• Khoo L, Matthews S, Kershaw G, et al. Case report of a fatal rectal haemorrhage in a person with severe haemophilia A receiving emicizumab and high-dose bypassing agents in the HAVEN 1 study. Haemoph Off J World Fed Hemoph. 2020;26:e340–2.
   PubMed Web of Science ®Google Scholar
• Hooimeijer HL, Lukens MV, Verhagen MV, et al. A boy with joint pain associated with emicizumab treatment: the importance of plasma level measurement. Haemoph Off J World Fed Hemoph. 2020;26:e138–40.
   PubMed Web of Science ®Google Scholar
• Chehade H, Cachat F, Beck-Popovic M, et al. Emicizumab-induced seronegative full-house lupus nephritis in a child. Pediatrics. 2020;146(5):e20200123.
   PubMed Web of Science ®Google Scholar
• Kruse-Jarres R, Kempton CL, Baudo F, et al. Acquired hemophilia A: updated review of evidence and treatment guidance. Am J Hematol. 2017;92(7):695–705.
   PubMed Web of Science ®Google Scholar
• Al-Banaa K, Alhillan A, Hawa F, et al. Emicizumab use in treatment of acquired hemophilia a: a case report. Am J Case Rep. 2019;20:1046–1048.
   PubMed Web of Science ®Google Scholar
• Hess KJ, Patel P, Joshi AM, et al. Utilization of emicizumab in acquired factor VIII deficiency. Am J Case Rep. 2020;21:e922326.
   PubMed Web of Science ®Google Scholar
• Santagostino E, Mancuso ME, Novembrino C, et al. Rescue factor VIII replacement to secure hemostasis in a patient with hemophilia A and inhibitors on emicizumab prophylaxis undergoing Hip replacement. Haematologica. 2019;104(8):e380–2.
   PubMed Web of Science ®Google Scholar
• Kizilocak H, Yukhtman CL, Marquez-Casas E, et al. Management of perioperative hemostasis in a severe hemophilia A patient with inhibitors on emicizumab using global hemostasis assays. Ther Adv Hematol. 2019;10:2040620719860025.
   Web of Science ®Google Scholar
• Chen Y-W, Chen W-J, Tseng M-S, et al. Consecutive complex percutaneous coronary interventions using emicizumab and recombinant activated factor VII in a patient with severe haemophilia A and high-titre inhibitor. Haemoph Off J World Fed Hemoph. 2021;27:e385–8.
   PubMed Web of Science ®Google Scholar
• Nagao A, Koganei H, Yamaguchi T, et al. Successful emicizumab prophylaxis during dual antiplatelet therapy for insertion of drug-eluting stents after acute coronary syndrome: a case report. Haemoph Off J World Fed Hemoph. 2021;27(4).
   Google Scholar
• Dane KE, Lindsley JP, Streiff MB, et al. Successful use of emicizumab in a patient with refractory acquired hemophilia A and acute coronary syndrome requiring percutaneous coronary intervention. Res Pract Thromb Haemost. 2019;3(3):420–423.
   PubMed Web of Science ®Google Scholar
• Seaman CD, Ragni MV. Emicizumab use in major orthopedic surgery. Blood Adv. 2019;3(11):1722–1724.
   PubMed Web of Science ®Google Scholar
• Biron-Andreani C, Diaz-Cau I, Ranc A, et al. Major surgery management in patients with haemophilia A and inhibitors on emicizumab prophylaxis without global coagulation monitoring. Br J Haematol. 2020;189(3):e100–3.
   PubMed Web of Science ®Google Scholar
• Okamoto S, Suzuki N, Suzuki A, et al. Successful perioperative combination of high-dose FVIII therapy followed by emicizumab in a patient with hemophilia a with inhibitors. TH Open Companion J Thromb Haemost. 2019;3. e364–6.
   PubMedGoogle Scholar
• Kageyama Y, Matsumoto T, Tawara I, et al. Life-threatening tongue and retropharyngeal hemorrhage in a patient with hemophilia A with inhibitors. Am J Case Rep. 2019;20:1022–1026.
   PubMed Web of Science ®Google Scholar
• Teo HKW, Wong WH, Lam JCM. Recurrent intracranial bleed in a child receiving prophylaxis with emicizumab. Haemoph Off J World Fed Hemoph. 2021;27:e415–8.
   PubMed Web of Science ®Google Scholar
• Urbaniak-Kujda D, Biernat MM, Skalec T, et al. Successful treatment of COVID-19 in a patient with severe haemophilia A on emicizumab prophylaxis in the intensive care unit. Haemoph Off J World Fed Hemoph. 2021;27(4).
   Google Scholar
• Connors JM, Levy JHCOVID-19. and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033–2040.
   PubMed Web of Science ®Google Scholar
• Dorgalaleh A, Dabbagh A, Tabibian S, et al. Patients with congenital bleeding disorders appear to be less severely affected by SARS-CoV-2: is inherited hypocoagulability overcoming acquired hypercoagulability of coronavirus disease 2019 (COVID-19)? Semin Thromb Hemost. 2020;46(7):853–855.
   PubMedGoogle Scholar
• Rivas-Pollmar MI, Álvarez-Román MT, Butta-Coll NV, et al. Thromboprophylaxis in a patient with COVID-19 and severe hemophilia A on emicizumab prophylaxis. J Thromb Haemost JTH. 2020;18(9):2202–2204.
   PubMed Web of Science ®Google Scholar
• Cefalo MG, Ronco F, Di Felice G, et al. Effectiveness of emicizumab in preventing life-threatening bleeding complications in type 3 von Willebrand disease with inhibitors: a paediatric report. Haemoph Off J World Fed Hemoph. 2021;27(4):e495–e497.
   PubMed Web of Science ®Google Scholar